Epimed International, Inc.
6 recall(s) on record — most severe on record: Class II.
Recalls by year
- Recalls (6)
Registered facilities (2)
- Epimed International, Inc. FEI 1643059 · TX
- EPIMED INTERNATIONAL, INC. FEI 1316297 · NY
Recalls & enforcement
- Class IITerminated2021-02-01Outer coating of the catheter may deteriorate and result in the coating to crack and/or potentially flake off
- Class IITerminated2020-02-21Incorrect expiration date on introduction cannula packaging.
- Class IITerminated2019-06-18Mislabeled - The product's labeling contains an incorrect size for the catheter included in the kit. The kit contains a 21 gauge catheter, however the labeling states a 12 gauge catheter is included.
- Class IICompleted2017-12-28Potential for stylet to protrude from the distal end of the catheter
- Class IITerminated2017-07-24Potential for partially incomplete seal of product, impacting sterility.
- Class IITerminated2016-04-22There is a possibility that the needles may have the potential to skive a catheters outer coating. If this were to occur, there exists the risk that a portion of the catheter could remain in the patient, which may require otherwise unnecessary medical invention.
Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. We restate the public record only — measured facts, never risk verdicts.
Cite this record
RegWarden. “Epimed International, Inc. — FDA compliance profile.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/company/oo-1316297-epimed-international-inc/
Alerts for Epimed International, Inc.
Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.
Want a one-page facility brief?
A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.